Just Armin, Olson Andrea J M, Arendshorst William J
Dept. of Cell and Molecular Physiology, 6341 Medical Biomolecular Research Bldg., CB#7545, School of Medicine, Univ. of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7545, USA.
Am J Physiol Renal Physiol. 2004 Apr;286(4):F660-8. doi: 10.1152/ajprenal.00368.2003. Epub 2003 Dec 16.
The vascular actions of endothelin-1 (ET-1) reflect the combination of vasoconstrictor ET(A) and ET(B) receptors on smooth muscle cells and vasodilator ET(B) receptors on endothelial cells. The present study investigated the contribution of ET receptor subtypes using a comprehensive battery of agonists and antagonists infused directly into the renal artery of anesthetized rats to evaluate the actions of each receptor class alone and their interactions. ET-1 (5 pmol) reduced renal blood flow (RBF) 25+/-1%. ET(A) antagonist BQ-123 attenuated this response to a 15+/-1% decrease in RBF (P < 0.01), indicating net constriction by ET(B) receptors. Combined receptor blockade (BQ-123+BQ-788) resulted in a renal vasoconstriction of 7+/-1% (P = 0.001 vs. BQ-123), supporting a constrictor action of ET(B) receptors. In marked contrast, the ET(B) antagonist BQ-788 enhanced the ET-1 RBF response to 60+/-5% (P < 0.001), suggesting ET(B)-mediated net dilation. Consistent with ET(A) blockade, the ET(B) agonist sarafotoxin 6C (S6C) produced vasoconstriction, reducing RBF by 23+/-5%. Dose-response curves for ET-1 and S6C showed similar degrees of constriction between 0.2 and 100 pmol. Both antagonists (BQ-123, BQ-788) were equally effective at threefold lower than the standard doses, suggesting complete inhibition. We conclude that ET(B) receptors alone exert a net constrictor effect but cause a net dilator influence when costimulated with ET(A) receptors. Such opposing actions indicate more complex than additive interaction between receptor subtypes. Model analysis suggests ET(A)-mediated constriction is appreciably greater without than with costimulation of ET(B) receptors. Possible explanations include ET-1 clearance by ET(B) receptors and/or a dilator ET(B) receptor function that counteracts constriction.
内皮素 -1(ET -1)的血管作用反映了平滑肌细胞上的血管收缩性ET(A)和ET(B)受体与内皮细胞上的血管舒张性ET(B)受体的共同作用。本研究通过向麻醉大鼠的肾动脉直接输注一系列全面的激动剂和拮抗剂,来研究ET受体亚型的作用,以单独评估每种受体类型的作用及其相互作用。ET -1(5皮摩尔)使肾血流量(RBF)降低25±1%。ET(A)拮抗剂BQ -123将这种反应减弱至RBF降低15±1%(P < 0.01),表明ET(B)受体产生净收缩作用。联合受体阻断(BQ -123 + BQ -788)导致肾血管收缩7±1%(与BQ -123相比,P = 0.001),支持ET(B)受体的收缩作用。与之形成鲜明对比的是,ET(B)拮抗剂BQ -788将ET -1对RBF的反应增强至60±5%(P < 0.001),提示ET(B)介导的净舒张作用。与ET(A)阻断一致,ET(B)激动剂沙拉毒素6C(S6C)产生血管收缩,使RBF降低23±5%。ET -1和S6C的剂量 - 反应曲线显示在0.2至100皮摩尔之间收缩程度相似。两种拮抗剂(BQ -123、BQ -788)在比标准剂量低三倍时同样有效,表明完全抑制。我们得出结论,单独的ET(B)受体发挥净收缩作用,但与ET(A)受体共同刺激时会产生净舒张影响。这种相反的作用表明受体亚型之间存在比相加作用更复杂的相互作用。模型分析表明,在没有ET(B)受体共同刺激时,ET(A)介导 的收缩作用明显更强。可能的解释包括ET(B)受体对ET -1的清除作用和/或抵消收缩作用的舒张性ET(B)受体功能。